Evidence map›Paper›PMID 28093634›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2017

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.

A Diez-Perez, K E Naylor, B Abrahamsen, D Agnusdei, M L Brandi, C Cooper, E Dennison, E F Eriksen, D T Gold, N Guañabens and 13 more

Open access · greenAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 5 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Guideline
  6. Trial
  7. Trial
  8. Trial
  9. Systematic screening using FRAXOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Trial
  10. Trial
  11. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
    Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Observational
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 19 institutions in 12 countries.

A Diez-PerezDepartment of Internal Medicine, Hospital del Mar-IMIM-Universitat Autònoma and CIBERFES-ISCIII, P Maritim 25-29, 08003, Barcelona, Spain. adiez@parcdesalutmar.cat.
K E NaylorAcademic Unit of Bone Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK.
B AbrahamsenInstitute of Clinical Research, Odense Patient Data Explorative Network, University of Southern Denmark, Odense, Denmark.
D AgnusdeiIndependent Scientific Consultant, Florence, Italy.
M L BrandiMineral and Bone Metabolic Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
C CooperMRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK.
E DennisonMRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK.
E F EriksenDepartment of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital and University of Oslo, Oslo, Norway.
D T GoldDuke University Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA.
N GuañabensRheumatology Department, Hospital Clínic, University of Barcelona, CIBERehd, Barcelona, Spain.
P HadjiDepartment of Bone Oncology, Endocrinology and Reproductive Medicine, Nordwest Hospital, Frankfurt, Germany.
M HiligsmannDepartment of Health Services Research, School for Public Health & Primary Care (CAPHRI), Maastricht University, Maastricht, The Netherlands.
R HorneCentre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, UK.
R JosseDepartment of Nutritional Sciences and Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Canada.
J A KanisCentre for Metabolic Bone Diseases, Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK.
B Obermayer-PietschDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
D Prieto-AlhambraNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
J-Y ReginsterDepartment of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
R RizzoliService of Bone Diseases, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.
S SilvermanCedars-Sinai/University of California, Los Angeles, USA.
M C ZillikensDepartment of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
R EastellAcademic Unit of Bone Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK.
Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society
University of Sheffield · GBDuke University Hospital · USErasmus University Rotterdam · NLHolbæk Sygehus · DKInstituto de Salud Carlos III · ESKrankenhaus Nordwest · DEMaastricht University · NLMedical University of Graz · ATMRC Lifecourse Epidemiology Unit · GBNIHR Oxford Musculoskeletal Biomedical Research Centre · GBNuffield Orthopaedic Centre · GBSt. Michael's Hospital · CAUniversitat de Barcelona · ESUniversity College London · GBUniversity Hospital of Geneva · CHUniversity of California, Los Angeles · USUniversity of Florence · ITUniversity of Liège · BEUniversity of Oslo · NO

Funding

Medical Research Council G0400491Medical Research Council MC_U147574212Medical Research Council MC_U147574234Medical Research Council MC_U147574237Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1Versus Arthritis 19583
6 · The paper itself

Abstract

Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug.

introductionLow adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients.

methodsThe International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis.

resultsBased on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%.

conclusionsIf a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence.

Indexed as

Medication AdherenceAdministration, OralBiomarkersBone Density Conservation AgentsBone RemodelingCollagen Type IDiphosphonatesDrug Evaluation, PreclinicalFemaleHumansOsteoporosis, PostmenopausalPeptide FragmentsPeptidesProcollagenBiomarkersBone Density Conservation AgentsCollagen Type Icollagen type I trimeric cross-linked peptideDiphosphonatesPeptide FragmentsPeptidesProcollagenprocollagen Type I N-terminal peptideAdherenceBisphosphonatesOsteoporosis treatmentPosition paperScreening

Identifiers

PMID28093634
PMCPMC5302161
OpenAlexW2574774326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.